Download PDF
J Neurol Surg B Skull Base 2021; 82(S 03): e166-e171
DOI: 10.1055/s-0040-1708854
Original Article

Delaying Postoperative Radiotherapy in Low-Grade Esthesioneuroblastoma: Is It Worth the Wait?

Satoshi Kiyofuji 
1   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan
,
Vijay Agarwal
1   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Joshua D. Hughes
1   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Robert L. Foote
3   Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, United States
,
Jeffrey R. Janus
4   Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, United States
,
Eric J. Moore
4   Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, United States
,
Caterina Giannini
5   Department of Pathology, Mayo Clinic, Rochester, Minnesota, United States
,
Michael J. Link
1   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
4   Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, United States
,
Jamie J. Van Gompel 
1   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
4   Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Consensus in timing of radiotherapy is yet to be established in esthesioneuroblastoma (ENB).

Objective This study was aimed to investigate if planned adjuvant radiotherapy improves tumor control after complete margin negative resection of low Hyams' grade (1 or 2) ENB.

Methods A retrospective review of patients with pathologically confirmed negative margin resection of Kadish's stage B or C and Hyams' grade 1 and 2 ENBs was conducted. Seventeen patients meeting the criteria were divided into the following two groups for cohort study: (1) those who underwent planned immediate postoperative adjuvant radiotherapy (IR group) and (2) those who did not (delayed radiotherapy [DR] group).

Results The IR group included nine patients (Kadish's stage B in one and stage C in eight; Hyams' grade 1 in two and grade 2 in seven). Mean follow-up was 140.8 months. Seven patients (78%) had disease progression (DP) at a median of 88 months (four with cervical lymph node metastasis [CLNM], one with distant metastasis, and two with both local recurrence and CLNM). One patient experienced frontal lobe abscess. The DR group included eight patients (Kadish's stage B in six and stage C in two; all Hyams' grade 2). Mean follow-up was 123.3 months. Four (50%) patients who developed DP (all local recurrence) were salvaged with surgery and adjuvant radiotherapy at a median of 37.5 months. There was no statistically significant difference in DP rate (p = 0.23), time to DP (p = 0.26), or the local tumor control rate (p = 0.23).

Conclusion In our limited cohort, immediate postoperative radiotherapy did not demonstrate superiority in tumor control, although risk of radiotherapy toxicity appears low.

Keywords

craniofacial resection - esthesioneuroblastoma - intensity-modulated radiation therapy - olfactory neuroblastoma - surgical treatment


Publication History

Received: 20 August 2019

Accepted: 14 February 2020

Article published online:
25 March 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dias FL, Sa GM, Lima RA. et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129 (11) 1186-1192
    CrossrefPubMedGoogle Scholar
  • 2 Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123 (03) 433-439
    CrossrefPubMedGoogle Scholar
  • 3 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37 (03) 1571-1576
    CrossrefPubMedGoogle Scholar
  • 4 Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990; 100 (11) 1199-1201
    CrossrefPubMedGoogle Scholar
  • 5 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102 (08) 843-849
    CrossrefPubMedGoogle Scholar
  • 6 Hyams V. Tumors of the upper respiratory tract and ear. In: VJ Hyams JB, L Michaels, ed. Atlas of Tumor Pathology. Vol. 2. Washington, DC: Armed Forces Institute of Pathology; 1988: 240-248
    Google Scholar
  • 7 Kaur G, Kane AJ, Sughrue ME. et al. The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci 2013; 20 (02) 281-286
    CrossrefPubMedGoogle Scholar
  • 8 Peacock JG, Harmsen WS, Link MJ. et al. Risk of delayed lymph node metastasis in clinically no esthesioneuroblastoma. J Neurol Surg B Skull Base 2017; 78 (01) 68-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Van Gompel JJ, Giannini C, Olsen KD. et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base 2012; 73 (05) 331-336
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Van Gompel JJ, Link MJ, Sheehan JP. et al. Radiosurgery is an effective treatment for recurrent esthesioneuroblastoma: a multicenter study. J Neurol Surg B Skull Base 2014; 75 (06) 409-414
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Benfari G, Fusconi M, Ciofalo A. et al. Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital 2008; 28 (06) 292-297
    PubMedGoogle Scholar
  • 12 Suriano M, De Vincentiis M, Colli A, Benfari G, Mascelli A, Gallo A. Endoscopic treatment of esthesioneuroblastoma: a minimally invasive approach combined with radiation therapy. Otolaryngol Head Neck Surg 2007; 136 (01) 104-107
    CrossrefPubMedGoogle Scholar
  • 13 Xiong L, Zeng XL, Guo CK, Liu AW, Huang L. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients. BMC Cancer 2017; 17 (01) 254
    CrossrefPubMedGoogle Scholar
  • 14 Lapierre A, Selmaji I, Samlali H, Brahmi T, Yossi S. [Esthesioneuroblastoma: A single institution's experience and general literature review] (in French). Cancer Radiother 2016; 20 (08) 783-789
    CrossrefPubMedGoogle Scholar
  • 15 Eich HT, Müller RP, Micke O, Kocher M, Berthold F, Hero B. Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?. Strahlenther Onkol 2005; 181 (06) 378-384
    CrossrefPubMedGoogle Scholar
  • 16 Polin RS, Sheehan JP, Chenelle AG. et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery 1998; 42 (05) 1029-1037
    CrossrefPubMedGoogle Scholar
  • 17 McElroy Jr EA, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998; 42 (05) 1023-1027
    CrossrefPubMedGoogle Scholar
  • 18 Porter AB, Bernold DM, Giannini C. et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol 2008; 90 (02) 201-204
    CrossrefPubMedGoogle Scholar
  • 19 Miyamoto RC, Gleich LL, Biddinger PW, Gluckman JL. Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis. Laryngoscope 2000; 110 (08) 1262-1265
    CrossrefPubMedGoogle Scholar
  • 20 Koch M, Constantinidis J, Dimmler A, Strauss C, Iro H. [Long-term experiences in the therapy of esthesioneuroblastoma] (in German). Laryngorhinootologie 2006; 85 (10) 723-730
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Constantinidis J, Steinhart H, Koch M. et al. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg 2004; 130 (05) 567-574
    CrossrefPubMedGoogle Scholar
  • 22 Klironomos G, Gonen L, Au K. et al. Endoscopic management of Esthesioneuroblastoma: our experience and review of the literature. J Clin Neurosci 2018; 58: 117-123
    CrossrefPubMedGoogle Scholar
  • 23 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32 (05) 706-714
    CrossrefPubMedGoogle Scholar
  • 24 Castelnuovo P, Bignami M, Delù G, Battaglia P, Bignardi M, Dallan I. Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience. Head Neck 2007; 29 (09) 845-850
    CrossrefPubMedGoogle Scholar
  • 25 Castelnuovo PG, Delù G, Sberze F. et al. Esthesioneuroblastoma: endonasal endoscopic treatment. Skull Base 2006; 16 (01) 25-30
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Folbe A, Herzallah I, Duvvuri U. et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy 2009; 23 (01) 91-94
    CrossrefPubMedGoogle Scholar
  • 27 Devaiah AK, Larsen C, Tawfik O, O'Boynick P, Hoover LA. Esthesioneuroblastoma: endoscopic nasal and anterior craniotomy resection. Laryngoscope 2003; 113 (12) 2086-2090
    CrossrefPubMedGoogle Scholar
  • 28 Zanation AM, Ferlito A, Rinaldo A. et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol 2010; 267 (11) 1667-1671
    CrossrefPubMedGoogle Scholar
  • 29 Loy AH, Reibel JF, Read PW. et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006; 132 (02) 134-138
    CrossrefPubMedGoogle Scholar
  • 30 Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73 (02) 424-432
    CrossrefPubMedGoogle Scholar
  • 31 Duprez F, Madani I, Morbée L. et al. IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys 2012; 83 (01) 252-259
    CrossrefPubMedGoogle Scholar
  • 32 Dagan R, Bryant C, Li Z. et al. Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys 2016; 95 (01) 377-385
    CrossrefPubMedGoogle Scholar
  • 33 Nakamura N, Zenda S, Tahara M. et al. Proton beam therapy for olfactory neuroblastoma. Radiother Oncol 2017; 122 (03) 368-372
    CrossrefPubMedGoogle Scholar
  • 34 Lucas Jr JT, Ladra MM, MacDonald SM. et al. Proton therapy for pediatric and adolescent esthesioneuroblastoma. Pediatr Blood Cancer 2015; 62 (09) 1523-1528
    CrossrefPubMedGoogle Scholar
  • 35 Herr MW, Sethi RK, Meier JC. et al. Esthesioneuroblastoma: an update on the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. J Neurol Surg B Skull Base 2014; 75 (01) 58-64
    PubMedGoogle Scholar
  • 36 Kim HJ, Cho HJ, Kim KS. et al. Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma. J Craniomaxillofac Surg 2008; 36 (01) 47-52
    CrossrefPubMedGoogle Scholar
  • 37 Gore MR, Zanation AM. Salvage treatment of local recurrence in esthesioneuroblastoma: a meta-analysis. Skull Base 2011; 21 (01) 1-6
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Naples JG, Spiro J, Tessema B, Kuwada C, Kuo CL, Brown SM. Neck recurrence and mortality in esthesioneuroblastoma: Implications for management of the no neck. Laryngoscope 2016; 126 (06) 1373-1379
    CrossrefPubMedGoogle Scholar
  • 39 Monroe AT, Hinerman RW, Amdur RJ, Morris CG, Mendenhall WM. Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation. Head Neck 2003; 25 (07) 529-534
    CrossrefPubMedGoogle Scholar
  • 40 Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133 (03) 276-280
    CrossrefPubMedGoogle Scholar